Migraine - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Migraine - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Migraine: Overview
Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. A migraine is a type of headache with symptoms that can differ from those of non-migraine headaches. These may include unusual symptoms that can be scary, like tingling sensations, flashing lights, weird sounds, and blurred or lost vision.
There's no cure for migraine headaches. But many drugs can treat or even prevent them. Common migraine treatments include: Pain relief- Over-the-counter (OTC) drugs often work well. The main ingredients are acetaminophen, aspirin, caffeine, and ibuprofen. Triptans- These drugs balance the chemicals in brain, includes almotriptan (Axert), eletriptan (Relpax), sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan (Zomig).
Report Highlights
This segment of the Migraine report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Migraine Emerging Drugs
It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.
It is currently in Phase III stage of development for Migraine and is being developed by Satsuma Pharmaceuticals.
Further product details are provided in the report..
Migraine: Therapeutic Assessment
This segment of the report provides insights about the different Migraine drugs segregated based on following parameters that define the scope of the report, such as:
Migraine: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Migraine therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Migraine drugs.
Migraine Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Migraine - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Migraine: Overview
Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. A migraine is a type of headache with symptoms that can differ from those of non-migraine headaches. These may include unusual symptoms that can be scary, like tingling sensations, flashing lights, weird sounds, and blurred or lost vision.
There's no cure for migraine headaches. But many drugs can treat or even prevent them. Common migraine treatments include: Pain relief- Over-the-counter (OTC) drugs often work well. The main ingredients are acetaminophen, aspirin, caffeine, and ibuprofen. Triptans- These drugs balance the chemicals in brain, includes almotriptan (Axert), eletriptan (Relpax), sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan (Zomig).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches for Migraine.
This segment of the Migraine report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Migraine Emerging Drugs
- Zavegepant: Biohaven Pharmaceuticals
It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.
- STS-101: Satsuma Pharmaceuticals
It is currently in Phase III stage of development for Migraine and is being developed by Satsuma Pharmaceuticals.
Further product details are provided in the report..
Migraine: Therapeutic Assessment
This segment of the report provides insights about the different Migraine drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Migraine
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Migraine: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Migraine therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Migraine drugs.
Migraine Report Insights
- Migraine Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Migraine drugs?
- How many Migraine drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Migraine?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Migraine therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Migraine and their status?
- What are the key designations that have been granted to the emerging drugs?
- Satsuma Pharmaceuticals
- Biohaven Pharmaceuticals
- Allodynic Therapeutics
- Vaxxinity
- AbbVie
- Pulmatrix
- AEON Biopharma
- Eli Lilly and Company
- Trevena
- Xoc Pharmaceuticals
- Pharmaleads
- Pear Therapeutics
- STS-101
- Zavegepant
- ALLOD-2
- UB-313
- Atogepant
- PUR-3100
- ABP-450
- LY3451838
- TRV250
- XC101
- PL37
Introduction
Executive Summary
Migraine: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Migraine– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Migraine companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Migraine Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Zavegepant: Biohaven Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
LY3451838: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
TRV250: Trevena
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
PUR-3100: Pulmatrix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Migraine Key Companies
Migraine Key Products
Migraine- Unmet Needs
Migraine- Market Drivers and Barriers
Migraine- Future Perspectives and Conclusion
Migraine Analyst Views
Migraine Key Companies
Appendix
Executive Summary
Migraine: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Migraine– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Migraine companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Migraine Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Zavegepant: Biohaven Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
LY3451838: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
TRV250: Trevena
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
PUR-3100: Pulmatrix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Migraine Key Companies
Migraine Key Products
Migraine- Unmet Needs
Migraine- Market Drivers and Barriers
Migraine- Future Perspectives and Conclusion
Migraine Analyst Views
Migraine Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Migraine
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Migraine
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Migraine
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Migraine
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
